Complications and Anatomical Considerations in Botulinum Neurotoxin Type A Injections for Upper Face Rejuvenation: A Systematic Review
DOI:
https://doi.org/10.12775/QS.2025.39.58445Keywords
Botulinum toxin, aesthetic medicine, ptosis, injection complication, botox, lipid profile, upper face anatomy, Botulinum neurotoxin type A, cosmetic dermatology, botulinum toxin injections, crow's feet, diplopia, review, eyelid, Injection-Site ReactionsAbstract
Botulinum neurotoxin type A (BoNT-A) is widely utilized in aesthetic medicine for the treatment of dynamic rhytides in the upper face. Despite its efficacy, the intricate anatomy of the upper face poses significant challenges, with potential complications ranging from transient injection-site reactions to more severe outcomes such as eyelid ptosis and facial asymmetry. This systematic review aims to provide a comprehensive analysis of the complications associated with BoNT-A injections in the upper face, focusing on the interplay between anatomical variations, injection techniques, and patient-specific factors. By synthesizing current clinical evidence, this review highlights the importance of precise anatomical knowledge, standardized injection protocols, and injector expertise in minimizing adverse effects. Furthermore, it offers evidence-based recommendations to enhance the safety and efficacy of BoNT-A treatments, ensuring optimal aesthetic outcomes while mitigating risks.
References
[1] J. D. A. Carruthers and J. A. Carruthers, “Treatment of Glabellar Frown Lines with C. Botulinum‐A Exotoxin,” J Dermatol Surg Oncol, vol. 18, no. 1, pp. 17–21, Jan. 1992, doi: 10.1111/j.1524-4725.1992.tb03295.x.
[2] M. F. Brin et al., “Safety and tolerability of onabotulinumtoxinA in the treatment of upper facial lines from global registration studies in 5298 participants: A meta-analysis,” JAAD Int, vol. 14, pp. 4–18, Mar. 2024, doi: 10.1016/j.jdin.2023.07.021.
[3] T. J. Walker and S. H. Dayan, “Comparison and overview of currently available neurotoxins.,” J Clin Aesthet Dermatol, vol. 7, no. 2, pp. 31–9, Feb. 2014.
[4] D. Hexsel and T. Dal’forno, “Type A botulinum toxin in the upper aspect of the face.,” Clin Dermatol, vol. 21, no. 6, pp. 488–97, 2003, doi: 10.1016/j.clindermatol.2003.11.002.
[5] M. S. Nestor, D. Arnold, and D. Fischer, “The mechanisms of action and use of botulinum neurotoxin type A in aesthetics: Key Clinical Postulates II,” J Cosmet Dermatol, vol. 19, no. 11, pp. 2785–2804, Nov. 2020, doi: 10.1111/jocd.13702.
[6] A. Biello and B. Zhu, Botulinum Toxin Treatment of the Upper Face. 2025.
[7] A. Borba, S. Matayoshi, and M. Rodrigues, “Avoiding Complications on the Upper Face Treatment With Botulinum Toxin: A Practical Guide,” Aesthetic Plast Surg, vol. 46, no. 1, pp. 385–394, Feb. 2022, doi: 10.1007/s00266-021-02483-1.
[8] A. C. Abramo, T. P. A. Do Amaral, B. P. Lessio, and G. A. De Lima, “Anatomy of Forehead, Glabellar, Nasal and Orbital Muscles, and Their Correlation with Distinctive Patterns of Skin Lines on the Upper Third of the Face: Reviewing Concepts,” Aesthetic Plast Surg, vol. 40, no. 6, pp. 962–971, Dec. 2016, doi: 10.1007/s00266-016-0712-z.
[9] É. P. Di Santis, S. H. Hirata, G. M. Di Santis, and S. Yarak, “Adverse effects of the aesthetic use of botulinum toxin and dermal fillers on the face: a narrative review,” An Bras Dermatol, vol. 100, no. 1, pp. 87–103, Jan. 2025, doi: 10.1016/j.abd.2024.04.007.
[10] S. Khan, G. Pathak, D. Milgraum, M. Tamhankar, and S. Milgraum, “Double vision due to lateral rectus injury after cosmetic botulinum toxin injections,” Australasian Journal of Dermatology, vol. 64, no. 3, Aug. 2023, doi: 10.1111/ajd.14120.
[11] A. Dolar Bilge, F. Sadigov, and S. Salar-Gomceli, “Sixth nerve palsy following botulinum toxin injection for facial rejuvenation,” Cutan Ocul Toxicol, vol. 36, no. 2, pp. 193–194, Apr. 2017, doi: 10.1080/15569527.2016.1227989.
[12] N. Sethi, S. Singh, K. DeBoulle, and E. Rahman, “A Review of Complications Due to the Use of Botulinum Toxin A for Cosmetic Indications,” Aesthetic Plast Surg, vol. 45, no. 3, pp. 1210–1220, Jun. 2021, doi: 10.1007/s00266-020-01983-w.
[13] D. Zargaran et al., “Complications of Cosmetic Botulinum Toxin A Injections to the Upper Face: A Systematic Review and Meta-Analysis,” Aesthet Surg J, vol. 42, no. 5, pp. NP327–NP336, Apr. 2022, doi: 10.1093/asj/sjac036.
[14] M. Cavallini et al., “Safety of Botulinum Toxin A in Aesthetic Treatments: A Systematic Review of Clinical Studies,” Dermatologic Surgery, vol. 40, no. 5, pp. 525–536, May 2014, doi: 10.1111/dsu.12463.
[15] J. Huang, X. Zhang, and Y. Chang, “Effectiveness and safety of botulinum toxin type A combined with blepharoplasty in treating sagging skin around the eyes.,” Heliyon, vol. 10, no. 18, p. e37407, Sep. 2024, doi: 10.1016/j.heliyon.2024.e37407.
[16] J. A. Carruthers et al., “A multicenter, double-blind, randomized, placebo-controlled study of the efficacy and safety of botulinum toxin type A in the treatment of glabellar lines,” J Am Acad Dermatol, vol. 46, no. 6, pp. 840–849, Jun. 2002, doi: 10.1067/mjd.2002.121356.
[17] A. D’Souza and C. L. Ng, “Applied Anatomy for Botulinum Toxin Injection in Cosmetic Interventions,” Curr Otorhinolaryngol Rep, vol. 8, no. 4, pp. 336–343, Dec. 2020, doi: 10.1007/s40136-020-00308-4.
[18] Z. P. Lorenc, S. Smith, M. Nestor, D. Nelson, and A. Moradi, “Understanding the Functional Anatomy of the Frontalis and Glabellar Complex for Optimal Aesthetic Botulinum Toxin Type A Therapy,” Aesthetic Plast Surg, vol. 37, no. 5, pp. 975–983, Oct. 2013, doi: 10.1007/s00266-013-0178-1.
[19] J. B. Kaplan, “Consideration of Muscle Depth for Botulinum Toxin Injections: A Three-Dimensional Approach,” Plastic Surgical Nursing, vol. 37, no. 1, pp. 32–38, Jan. 2017, doi: 10.1097/PSN.0000000000000172.
[20] M. R. Macdonald, J. H. Spiegel, R. B. Raven, S. S. Kabaker, and C. S. Maas, “An Anatomical Approach to Glabellar Rhytids,” Arch Otolaryngol Head Neck Surg, vol. 124, no. 12, p. 1315, Dec. 1998, doi: 10.1001/archotol.124.12.1315.
[21] R. DANIEL and B. LANDON, “Endoscopic forehead lift: Anatomic basis,” Aesthet Surg J, vol. 17, no. 2, pp. 97–104, Mar. 1997, doi: 10.1016/S1090-820X(97)80070-2.
[22] S. S. Raveendran and D. J. Anthony, “Classification and Morphological Variation of the Frontalis Muscle and Implications on the Clinical Practice,” Aesthetic Plast Surg, vol. 45, no. 1, pp. 164–170, Feb. 2021, doi: 10.1007/s00266-020-01937-2.
[23] B. E. Cook, M. J. Lucarelli, and B. N. Lemke, “Depressor Supercilii Muscle,” Ophthalmic Plast Reconstr Surg, vol. 17, no. 6, pp. 404–411, Nov. 2001, doi: 10.1097/00002341-200111000-00004.
[24] B. Knight, A. O. Fakoya, M. J. Lopez, and B. C. Patel, Anatomy, Head and Neck: Levator Palpebrae Superioris Muscle. 2025.
[25] M. S. Nestor, H. Han, A. Gade, D. Fischer, Y. Saban, and R. Polselli, “Botulinum toxin–induced blepharoptosis: Anatomy, etiology, prevention, and therapeutic options,” J Cosmet Dermatol, vol. 20, no. 10, pp. 3133–3146, Oct. 2021, doi: 10.1111/jocd.14361.
[26] S. Omoigui and S. Irene, “Treatment of Ptosis as a Complication of Botulinum Toxin Injection,” Pain Medicine, vol. 6, no. 2, pp. 149–151, Mar. 2005, doi: 10.1111/j.1526-4637.2005.05029.x.
[27] I. J. Musharbash and R. J. Chakra, “Treatment of Full Eyelid Ptosis Following Botox Injection: A Case Report,” Cureus, Mar. 2024, doi: 10.7759/cureus.55970.
[28] G. F. Alotaibi, S. F. Alsukait, H. H. Alsalman, and M. G. Turkmani, “Eyelid ptosis following botulinum toxin injection treated with brimonidine 0.33% topical gel,” JAAD Case Rep, vol. 22, pp. 96–98, Apr. 2022, doi: 10.1016/j.jdcr.2022.01.019.
[29] M. B. Kashkouli, A. Amani, M. Jamshidian-Tehrani, S. Yousefi, and A. A. Jazayeri, “Eighteen-Point Abobotulinum Toxin A Upper Face Rejuvenation,” Ophthalmic Plast Reconstr Surg, vol. 30, no. 3, pp. 219–224, May 2014, doi: 10.1097/IOP.0000000000000053.
[30] J. Carruthers and A. Carruthers, “Complications of Botulinum Toxin Type A,” Facial Plast Surg Clin North Am, vol. 15, no. 1, pp. 51–54, Feb. 2007, doi: 10.1016/j.fsc.2006.10.004.
[31] D. Ho, J. Jagdeo, and H. A. Waldorf, “Is There a Role for Arnica and Bromelain in Prevention of Post-Procedure Ecchymosis or Edema? A Systematic Review of the Literature,” Dermatologic Surgery, vol. 42, no. 4, pp. 445–463, Apr. 2016, doi: 10.1097/DSS.0000000000000701.
[32] B. Ascher et al., “International consensus recommendations on the aesthetic usage of botulinum toxin type A (Speywood Unit) – part II: wrinkles on the middle and lower face, neck and chest,” Journal of the European Academy of Dermatology and Venereology, vol. 24, no. 11, pp. 1285–1295, Nov. 2010, doi: 10.1111/j.1468-3083.2010.03728.x.
[33] M. Alam, K. A. Arndt, and J. S. Dover, “Severe, intractable headache after injection with botulinum a exotoxin: Report of 5 cases,” J Am Acad Dermatol, vol. 46, no. 1, pp. 62–65, Jan. 2002, doi: 10.1067/mjd.2001.118342.
[34] E. Shahverdi, H. Molaee, A. Dehghanian, and M. Allahverdi Khani, “Recurrent Swelling and Edema after Botulinum Toxin Type A Injection in the Upper Face; A Case Report,” Focus on Sciences, vol. 2, no. 4, pp. 1–10, Oct. 2016, doi: 10.21859/focsci-020442.
[35] A. J. Vartanian and S. H. Dayan, “Complications of botulinum toxin A use in facial rejuvenation,” Facial Plast Surg Clin North Am, vol. 13, no. 1, pp. 1–10, Feb. 2005, doi: 10.1016/j.fsc.2004.04.008.
[36] A. Redaelli and R. Forte, “How to avoid brow ptosis after forehead treatment with botulinum toxin,” Journal of Cosmetic and Laser Therapy, vol. 5, no. 3–4, pp. 220–222, Dec. 2003, doi: 10.1080/14764170310023254.
[37] A. CARRUTHERS and J. CARRUTHERS, “Clinical Indications and Injection Technique for the Cosmetic Use of Botulinum A Exotoxin,” Dermatologic Surgery, vol. 24, no. 11, pp. 1189–1194, Nov. 1998, doi: 10.1111/j.1524-4725.1998.tb04097.x.
[38] G. Kroumpouzos, M. Kassir, M. Gupta, A. Patil, and M. Goldust, “Complications of Botulinum toxin A: An update review.,” J Cosmet Dermatol, vol. 20, no. 6, pp. 1585–1590, Jun. 2021, doi: 10.1111/jocd.14160.
[39] S. Akkaya, H. K. Kökcen, and T. Atakan, “Unilateral transient mydriasis and ptosis after botulinum toxin injection for a cosmetic procedure,” Clinical Ophthalmology, p. 313, Feb. 2015, doi: 10.2147/OPTH.S76054.
[40] R. Skorochod, R. Nesher, G. Nesher, and Y. Gronovich, “Ophthalmic adverse events following facial injections of botulinum toxin A: A systemic literature review,” J Cosmet Dermatol, vol. 20, no. 8, pp. 2409–2413, Aug. 2021, doi: 10.1111/jocd.14279.
[41] S. A. Kaltreider et al., “Cosmetic oculofacial applications of botulinum toxin: a report by the American Academy of Ophthalmology.,” Ophthalmology, vol. 112, no. 6, pp. 1159–67, Jun. 2005, doi: 10.1016/j.ophtha.2005.03.021.
[42] H. Witmanowski and K. Błochowiak, “The whole truth about botulinum toxin – a review,” Advances in Dermatology and Allergology, vol. 37, no. 6, pp. 853–861, 2020, doi: 10.5114/ada.2019.82795.
[43] Ö. E. Yücel and N. Aritürk, “Botulinum Toxin-A–Induced Protective Ptosis in the Treatment of Lagophthalmos Associated With Facial Paralysis,” Ophthalmic Plast Reconstr Surg, vol. 28, no. 4, pp. 256–260, Jul. 2012, doi: 10.1097/IOP.0b013e31824ee702.
[44] J. Dubow, A. Kim, J. Leikin, K. Cumpston, S. Bryant, and M. Rezak, “Visual system side effects caused by parasympathetic dysfunction after botulinum toxin type B injections,” Movement Disorders, vol. 20, no. 7, pp. 877–880, Jul. 2005, doi: 10.1002/mds.20466.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Maria Kąpa, Bartosz Szepietowski, Jan Szustak, Michał Wijata, Anna Maria Wijata, Zuzanna Adriana Przybyłek-Stępień, Ryszard Bartosiński, Jakub Marek Kaźmierczak, Ewelina Rycerz, Wiktoria Mączyńska, Justyna Dutkiewicz, Piotr Pasek
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Stats
Number of views and downloads: 192
Number of citations: 0
